1379670-84-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2,2-trichloroethanone is used as a potential anticancer agent for its ability to target and inhibit the growth of cancer cells. The addition of the bromo group to the pyrrolopyridine core may enhance the compound's biological activity, making it a promising candidate for further drug development.
Used in Medicinal Chemistry Research:
1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,2,2-trichloroethanone is used as a target for medicinal chemistry research due to its unique chemical structure and potential for chemical modifications. The trichloroethanone moiety provides a reactive site for further chemical modifications, allowing researchers to explore its potential in drug discovery and development.

Upstream product

• 76-02-8 trifluoroacetyl chloride 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1379669-93-8 3-[5-(3-fluorobenzyl)-1,3,4-oxadiazol-2-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1429309-37-4 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxamide 
• 1379670-87-7 5-bromo-3-[5-(3-fluorobenzyl)-1,3,4-oxadiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine 
• 1379670-86-6 5-bromo-3-[5-(3-fluorobenzyl)-1H-1,2,4-triazol-3-yl]-1H-pyrrolo[2,3-b]pyridine 
• 1379669-87-0 3-[5-(3-fluorobenzyl)-1H-1,2,4-triazol-3-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 849068-61-7 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS

Compounds of the formula I in which Q, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are PDK1 inhibitors and can be employed for the treatment of tumours.

NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID

The present invention relates to new compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containin

COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.